MapLight Therapeutics officer proposes $79.4K sale
The stated purpose is to satisfy tax-withholding obligations tied to restricted stock unit vesting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. officer Jonathan Gillis reported a proposed sale of 10,167 common shares, with an aggregate market value of $79,404.27 and an approximate sale date of October 15, 2026. The shares are to be sold solely to satisfy tax-withholding obligations connected with restricted stock unit vesting. The notice lists Jefferies LLC as broker and Nasdaq as the exchange.
Key Figures
Key Terms
Restricted Stock Unit Grant financial
tax-withholding obligations financial
Rule 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.